8-K: Calidi Biotherapeutics Reports Q3 2026 Results, Advances Pipeline

Calidi Biotherapeutics announced third quarter 2026 financial results, highlighting progress in its CLD-401 program, reduced G&A expenses, and a capital raise.

Summary

• Calidi Biotherapeutics reported its third quarter 2026 financial results and business highlights.
• The company advanced its CLD-401 program towards clinical trials and presented new data on its RedTail platform at the ESMO Congress 2026.
• Calidi received $1.2 million in gross proceeds from an at-the-market registered direct offering.
• General and administrative expenses were reduced by $1.0 million (39%) in Q3 2026 compared to Q3 2025, and by $3.6 million (42%) for the nine months ended September 30, 2026.
• A restructuring plan, including headcount reduction, was executed on November 6, 2026, expected to save $3 million annually and extend cash runway.
• The company reported a net loss of $3.6 million for Q3 2026, an improvement from $10.8 million in Q3 2025, which included a significant non-cash charge.
• Research and development expenses were $2.7 million in Q3 2026, up from $2.4 million in Q3 2025.
• Cash and cash equivalents were $3.9 million as of September 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, with significant progress in R&D and cost reduction, but still facing substantial net losses and the need for future capital.

Positives

• Demonstrated significant reduction in general and administrative expenses by $1.0 million (39%) in Q3 2026 and $3.6 million (42%) year-to-date, extending cash runway.
• Advanced the CLD-401 program towards clinical trials, showing promising preclinical anti-tumor activity with complete tumor eradication in 80% of treated mice.
• Presented new preclinical data on the RedTail platform and in situ T-cell engager (TCE) platform at the ESMO Congress 2026.
• Received $1.2 million in gross proceeds from an at-the-market registered direct offering.
• Reduced net loss attributable to common stockholders to $3.6 million in Q3 2026 from $10.8 million in Q3 2025, partly due to the absence of a large non-cash charge.
• Restructuring plan executed to save $3 million annually and extend operating runway.

Negatives

• Reported a net loss of $3.6 million for the third quarter of 2026.
• The company had $3.9 million in cash and cash equivalents as of September 30, 2026, which may be insufficient for future clinical trials without additional capital.
• Research and development expenses increased to $2.7 million in Q3 2026 from $2.4 million in Q3 2025.

Risks

• Risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials.
• Risk that early clinical trial results do not predict final results, and outcomes may change with more comprehensive data review.
• Risk that Calidi may not receive FDA approval for its therapeutic candidates.
• Uncertainty regarding the timing, cost, and results of research and development activities and preclinical studies.
• Potential for changes in applicable laws or regulations.
• Manufacturing and supply chain matters could pose risks.
• Changes in business, market, economic, or competitive conditions.

Future Outlook

The company plans to dose the first patient in a Phase 1 clinical study in the second half of 2027. The restructuring is expected to extend the company's cash runway and operating runway.

Management Comments

• "Throughout the third quarter, Calidi continued to advance its RedTail platform for systemic and local delivery and redefine the potential of oncolytic viruses and genetic medicine."
• "In particular, CLD-401 demonstrated remarkable anti-tumor activity with systemic administration in syngeneic tumor models and continues to progress towards the clinic."

Industry Context

StockSavvy.ai notes that Calidi Biotherapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on novel genetic medicines. The company's progress with CLD-401 and its RedTail platform aligns with broader industry trends towards targeted therapies and advanced virotherapies, though significant challenges remain in clinical development and funding.

Comparison to Industry Standards

• Preclinical data for CLD-401 showed complete tumor eradication in 80% of EMT6 breast cancer tumor-bearing mice, which is a strong indicator of potential efficacy compared to historical benchmarks in similar preclinical models.
• The reduction in G&A expenses by 39% in Q3 2026 is a positive operational efficiency measure, often a focus for early-stage biotech companies managing burn rates.
• The net loss of $3.6 million in Q3 2026, while substantial, represents a significant improvement over the prior year's loss of $10.8 million, indicating progress in financial management or operational scaling.

Related Party Transactions

• Related party accounts payable of $18 as of September 30, 2026, compared to $18 as of December 31, 2025.
• Related party accrued expenses and other current liabilities of $0 as of September 30, 2026, compared to $530 as of December 31, 2025.
• Interest expense related party of $8 for the three months ended September 30, 2026.
• Change in fair value of other liabilities and derivatives related party of $5 for the three months ended September 30, 2026.
• Related party warrant liability of $0 as of September 30, 2026, compared to $8 as of December 31, 2025.

Stakeholder Impact

• Shareholders may see potential upside from pipeline advancements but face risks related to funding and clinical trial success.
• Employees may be impacted by the recent restructuring and headcount reduction.
• Creditors and suppliers will be impacted by the company's ongoing need for capital and its efforts to manage expenses.

Next Steps

• Continue advancing the development of CLD-401 towards the clinic.
• Pursue additional financing to support operations and clinical trials.
• Dose the first patient in a Phase 1 clinical study in the second half of 2027.

Key Dates

Recommendation

The company shows promising preclinical data and has made strides in cost reduction and operational efficiency. However, the significant net losses, ongoing need for capital, and the inherent risks of drug development warrant a cautious 'hold' rating until further clinical validation and funding clarity emerge.

Keywords

biotechnology, genetic medicine, oncolytic virus, CLD-401, RedTail platform, T-cell engager, ESMO Congress, clinical trials